NYSE:EBSBiotechs
Emergent BioSolutions (EBS) Stock Sinks As NARCAN Impairment Deepens Losses
Emergent BioSolutions came into this earnings print as a beaten down biotech, with the stock already down sharply over the past three months and now dropping another 8.9% to about US$4.84 after the release. The headline is not the top line. Q2 revenue of US$234.3m and adjusted EBITDA strength from its Medical Countermeasures business landed against a stark reality on the income statement. The company reported a Q2 net loss of US$180.2m, driven in large part by a large non cash impairment tied...